603 件 ・ 関連度順
概要と使いどころ
Audit code against NASA JPL's Power of Ten rules, extended for AI-assisted development. Use when checking code for dangerous complexity, unsafe control flow, resource leaks, hidden side effects, missing validation, weak CI gates, AI-generated artifacts, or missing failure-mode tests.
日本語の概要は準備中です。原文の説明を表示しています。
Svelte 5 runes system for reactive state management and side effects
日本語の概要は準備中です。原文の説明を表示しています。
Universal Adobe application automation via ExtendScript bridge. Supports Photoshop, Illustrator, InDesign, Premiere Pro, and After Effects.
日本語の概要は準備中です。原文の説明を表示しています。
Implement or review dygo Record lifecycle Hooks in Business Apps or the Hook runtime. Use for validation, transactional Record reactions, and lifecycle side effects tied to Record changes.
日本語の概要は準備中です。原文の説明を表示しています。
Implement signal-based reactive state management in Angular v20+. Use for creating reactive state with signal(), derived state with computed(), dependent state with linkedSignal(), and side effects with effect(). Triggers on state management questions, converting from BehaviorSubject/Observable patterns to signals, or implementing reactive data flows.
日本語の概要は準備中です。原文の説明を表示しています。
Add CSS animations to HTML elements, React/JSX components, or WordPress PHP templates using Animate.css (v4.1.1). Use this skill whenever the user wants to animate UI elements, add entrance/exit effects, attention-seeker animations, or any CSS-based motion to their markup. Trigger on phrases like "add animation", "animate this", "make it bounce/fade/slide/zoom", "add transitions", "CSS animations", or any request to bring elements to life visually. Works with raw HTML snippets, full HTML files, React JSX, and WordPress PHP templates. Claude picks the most contextually appropriate animation — no guesswork needed from the user.
日本語の概要は準備中です。原文の説明を表示しています。
Calculate statistical power and sample sizes for RCTs. Use when user mentions: power analysis, sample size calculation, minimum detectable effect, MDE, statistical power, effect size, clustering effects, design effect, ICC, intra-cluster correlation.
日本語の概要は準備中です。原文の説明を表示しています。
Causal inference with treatment/control groups over time. Use when user mentions: treatment effects, policy evaluation, pre/post comparison, parallel trends, DID, DiD, difference in differences, natural experiment, quasi-experimental.
日本語の概要は準備中です。原文の説明を表示しています。
Implementing the `Idempotency-Key` HTTP header pattern (Stripe-pioneered, IETF-standardizing) so retries don't double-charge or duplicate side effects — full Postgres schema with recovery-point state machine, fingerprint check, in-progress lock with 409 response, and 24h retention. Grounded in Stripe blog/docs, the IETF httpapi WG draft, and Brandur Leach's canonical implementation.
日本語の概要は準備中です。原文の説明を表示しています。
Safety, privacy, cost management, and frank advice for building always-on AI agents with episodic memory. Covers data hygiene, privacy risk surfaces, runaway cost prevention, scope creep, psychological effects of persistent AI companions, and responsible deployment patterns. This is the skill that tells you what can go wrong and how to prevent it. Activate on: "agent safety", "always-on agent privacy", "agent cost control", "persistent agent risks", "AI companion safety", "agent data hygiene", "runaway agent costs", "parasocial AI risk", "/always-on-agent-safety". NOT for: architecture design (use always-on-agent-architecture), input design (use always-on-agent-inputs), application brainstorming (use always-on-agent-applications), healthcare compliance specifically (use hipaa-compliance).
日本語の概要は準備中です。原文の説明を表示しています。
Design performant animation systems with Framer Motion, GSAP, View Transitions API, and spring physics. Activate on: page transitions, micro-interactions, scroll animations, layout animations, spring physics. NOT for: CSS-only hover effects (use css-in-js-architect), video/canvas rendering (use creative-coding-expert).
日本語の概要は準備中です。原文の説明を表示しています。
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
Handles batch effects in bulk RNA-seq via design-matrix inclusion (the correct path for DE), ComBat/ComBat-seq for visualization, SVA for unknown latent factors, RUVSeq for negative-control-gene-anchored unwanted variation, and limma::removeBatchEffect for plotting only. Encodes the Nygaard 2016 cardinal sin against testing on a batch-corrected matrix, the choice between SVA/RUVg/RUVs/RUVr, the confounding non-identifiability problem, the single-cell boundary (Harmony/MNN are NOT for bulk), and the Goh 2017 harmonization critique. Use when designing a DE analysis with batch structure, troubleshooting batch-dominated PCA, choosing ComBat vs ComBat-seq, handling unknown batch via SVA, integrating across studies, or deciding when (rarely) to subtract batch.
日本語の概要は準備中です。原文の説明を表示しています。
Build forest plots (HR, OR, RR, beta-coefficient summaries with CIs) and funnel plots (meta-analysis publication-bias diagnostics) using forestplot, metafor, ggforest, and MendelianRandomization with proper axis-scaling, summary-diamond placement, subgroup nesting, and Egger / trim-and-fill asymmetry tests. Use when summarizing effects across subgroups, trials, or instruments — meta-analysis, Mendelian randomization, subgroup HRs.
日本語の概要は準備中です。原文の説明を表示しています。
Predict RBP binding from RNA sequence using deep learning models (RBPNet sequence-to-signal, RNAProt RNN, GraphProt2 GCN with structure, DeepCLIP, DeepRiPe multi-modal CNN) for variant-effect prediction, in silico binding-site discovery, model interpretation, and transfer learning from CLIP and RBNS datasets. Use when computational prediction of RBP binding from sequence is needed, evaluating variant effects on binding without further wet-lab experiments, comparing model performance, or training a custom model on ENCODE eCLIP data.
日本語の概要は準備中です。原文の説明を表示しています。
Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.
日本語の概要は準備中です。原文の説明を表示しています。
Fits structural equation models to GWAS summary statistics using GenomicSEM (Grotzinger 2019), including common-factor models, confirmatory factor models, ESEM, common-factor GWAS with Q_SNP heterogeneity, multivariate Wald tests, and stratified GenomicSEM partitioned heritability. Reconciles results against MTAG multi-trait analysis. Handles sample overlap via the LDSC sampling-covariance matrix, identifies and resolves Heywood cases, and verifies model fit with CFI / RMSEA. Use when modeling latent genetic architecture across correlated traits, running multivariate GWAS on a shared factor, distinguishing factor-mediated from trait-specific SNP effects, or comparing GenomicSEM common-factor results against MTAG when both depend on accurate sampling covariance.
日本語の概要は準備中です。原文の説明を表示しています。
Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Trains and applies base-resolution deep learning models on ChIP-seq / ChIP-nexus / CUT&RUN data. Uses BPNet (Avsec 2021 Nat Genet 53:354; soft motif syntax from ChIP-nexus), chromBPNet (Pampari A et al 2024 bioRxiv; bias-factorized base-resolution profiles), EnFormer (Avsec 2021 Nat Methods 18:1196; 196 kb input, ~100 kb effective receptive field), DeepSEA (Zhou 2015; multi-task CNN), and JASPAR 2026 deep-learning collection (1259 BPNet ChIP models). Performs in silico mutagenesis for variant-effect prediction, DeepLIFT/Grad attribution, and TF-MoDISco motif discovery from attribution scores. Use when predicting variant effects on TF binding, discovering soft motif syntax / cooperativity, integrating ChIP-seq with sequence-only predictions, or applying precomputed JASPAR Deep Learning models to new variants.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Sequence-based deep learning for ATAC-seq using chromBPNet, BPNet, scBasset, or Enformer. Use when correcting Tn5 bias with neural networks beyond k-mer models, predicting per-base accessibility profiles, scoring in silico variant effects at GWAS or rare-variant SNPs, discovering motifs via DeepLIFT/TF-MoDISco from a trained model, or generating cell-type-specific accessibility predictions for unobserved cell states.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends using radiation therapy for corticotroph adenomas in Cushing's disease when imaging shows invasive features or mass‑effect concerns such as cavernous sinus invasion, suprasellar extension, or knobby protrusion. Consider RT when postoperative medical therapy has normalized cortisol but tumor progression or residual invasive disease is suspected.
日本語の概要は準備中です。原文の説明を表示しています。
Selects spironolactone as first-line mineralocorticoid receptor antagonist for bilateral primary aldosteronism, with eplerenone as an alternative when spironolactone–related adverse effects are problematic. Trigger phrases include 'confirmed bilateral PA on AVS', 'idiopathic adrenal hyperplasia', 'bilateral adrenal hyperplasia', 'glucocorticoid-remediable aldosteronism', and 'initiating medical therapy for bilateral adrenal disease'.
日本語の概要は準備中です。原文の説明を表示しています。